Filing Details
SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed a Form 8-K with the Securities and Exchange Commission on July 07, 2026, disclosing a material event.
8k filedNASDAQ:SABS
SAB Biotherapeutics, Inc. (SABS) Reports Material Event to SEC
Filing Details SAB Biotherapeutics, Inc. (NASDAQ:SABS) filed a Form 8-K with the Securities and Exchange Commission on July 07, 2026, disclosing a material event. Market Context…
Market Context
SAB Biotherapeutics, Inc.'s stock currently trades at $3.90 with a market capitalization of $34.3M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for SAB Biotherapeutics, Inc.'s stock.
All SEC filings for SAB Biotherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SABS Stock Page
Frequently Asked Questions
Where can I read SABS's SEC filings?
Browse all filings on our SABS SEC filings page.
What types of SEC filings does SAB Biotherapeutics, Inc. file?
Public companies like SAB Biotherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.